Study finds that lung cancer patients respond to erlotinib following cetuximab therapy

Non-small cell lung cancer patients who have progressed on a cetuximab-containing regimen may respond to erlotinib, Fox Chase Cancer Center researchers reported today at the annual meeting of the International Association for the Study of Lung Cancer.

Read the whole article on Physorg

More from Physorg